Birmingham Capital Management Co. Inc. AL Sells 10,344 Shares of Pfizer Inc. $PFE

Birmingham Capital Management Co. Inc. AL reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.0% in the first quarter, HoldingsChannel.com reports. The firm owned 163,243 shares of the biopharmaceutical company’s stock after selling 10,344 shares during the period. Pfizer comprises about 1.6% of Birmingham Capital Management Co. Inc. AL’s investment portfolio, making the stock its 24th largest holding. Birmingham Capital Management Co. Inc. AL’s holdings in Pfizer were worth $4,137,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC lifted its stake in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the period. Triumph Capital Management boosted its holdings in shares of Pfizer by 20.0% in the fourth quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 1,717 shares during the period. Gotham Asset Management LLC boosted its holdings in shares of Pfizer by 333.4% in the fourth quarter. Gotham Asset Management LLC now owns 141,040 shares of the biopharmaceutical company’s stock worth $3,742,000 after acquiring an additional 108,494 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in shares of Pfizer by 80.7% in the fourth quarter. Janus Henderson Group PLC now owns 958,315 shares of the biopharmaceutical company’s stock worth $25,434,000 after acquiring an additional 427,886 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.5%

PFE opened at $24.59 on Thursday. The company has a market cap of $139.79 billion, a P/E ratio of 13.08, a P/E/G ratio of 0.88 and a beta of 0.55. The business’s 50-day moving average price is $24.83 and its 200-day moving average price is $24.33. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on PFE shares. Citigroup raised their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Berenberg Bank lowered their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. HSBC lowered their price objective on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. Bank of America increased their price objective on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, Jefferies Financial Group increased their target price on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.